For the year ending 2025-12-31, ATOS had -$29,785K decrease in cash & cash equivalents over the period. -$29,785K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -34,770 |
| Stock-based compensation | 2,646 |
| Impairment charge on investment in equity securities | 0 |
| Depreciation | 16 |
| Loss on disposal of assets | 0 |
| Prepaid materials | 983 |
| Prepaid expenses and other current assets | -37 |
| Other assets | -4 |
| Accounts payable | 3,614 |
| Accrued expenses | 388 |
| Payroll liabilities | -304 |
| Other current liabilities | -410 |
| Net cash used in operating activities | -29,762 |
| Purchase of property and equipment | 23 |
| Net cash used in investing activities | -23 |
| Proceeds from exercise of warrants | 0 |
| Net cash provided by financing activities | 0 |
| Net decrease in cash, cash equivalents and restricted cash | -29,785 |
| Cash, cash equivalents and restricted cash, beginning balance | 71,194 |
| Cash, cash equivalents and restricted cash, ending balance | 41,409 |
ATOSSA THERAPEUTICS, INC. (ATOS)
ATOSSA THERAPEUTICS, INC. (ATOS)